The largest community for pharma industry

Meet our featured writers & subscribe to their newsletters

Tommaso Salanitri

Medical Affairs and Stakeholder Engagement in an Evolving Healthcare Scenario

Due to unprecedented challenging situation and the current pandemic time, stakeholders needs are changing and these uncertain times are accelerating approaches already existing within Pharma industry, in an era of digital disruption, therefore, more than in the past, flexible...

Tommaso Salanitri

Writer

TOMMASO SALANITRI´S ARCHIVES

Medical Affairs and Stakeholder Engagement in an Evolving Healthcare Scenario

Due to unprecedented challenging situation and the current pandemic time, stakeholders needs are changing and these uncertain times are...

“Go-to-Market”: Medical Affairs, Strategies and Timings

“Go-to-Market” in Pharma is defined as a tactical action plan, that outlines the needed steps to succeed in a...

Field Medical Affairs In Pharma/Biotech: Effectiveness, Opportunities and Challenges

  Medical Affairs has risen very fast in the last years, becoming after an initial phase of “supporting function”, a...

Medical Insights in Pharma Industry by Tommaso Salanitri

Gain an insight means obtain an accurate and deep understanding about some (complex) situation. Medical insights represent one of the most...

Business Analysis in Pharma Industry: from Market Research to Patient Journey. A Medical Affairs view

by Tommaso Salanitri, MD Business analysis in Pharma industry, either during the early phases of drug development phase or close...

Business Plan: a Medical Affairs perspective

A business plan is generally considered a process and specifically, a document, that summarizes the operational and financial objectives...

Suscribe to Tomasso Salanitri´s Newsletter

Natalie Yeadon

Working with, Advocating for, and Empowering Patients

A version of this article was previously published on Pharmaphorum. In recent years, there has been a clear shift in Pharma when it comes to how it interacts with patients. “Patient centricity” used to be pretty much just a buzzword,...

Natalie Yeadon

Impetus Digital Co-Owner/Managing Director

Natalie worked in the pharmaceutical industry for over 18 years in a variety of sales, marketing, and early brand commercialization management roles. Currently, she is the Co-owner and Managing Director of Impetus Digital where she dedicates her time to helping life science companies create sustained and authentic relationships with their key customers through Impetus’ cutting-edge online collaboration platform, the Impetus InSite Platform®.

MORE FROM NATALIE

“Fake News” and Credibility in Medical Publishing

A version of this article was previously published on Pharmaphorum. Doubtlessly, one of the defining phrases of the 2010s is...

Top 10 Most Important Advisor Questions

Today, I would like to share the top 10 most important advisor questions that every brand team should keep in mind...

Optimizing Survivorship Care in Oncology

I have previously discussed a range of topics related to the diagnosis and treatment of cancer, including the use...

Navigating Emerging Markets – Opportunities and Challenges for Pharma

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the...

The Zeigarnik Effect – What is it and how can it help increase productivity?

As I discussed in my recent webinar on the power of habit, habits, whether conscious or subconscious, are the...

Targeting the Tumor Microenvironment

Investigators are always looking for new and innovative ways to treat cancer. This is a constantly and rapidly evolving...

Why Pharma Needs to Care About Global Warming

A version of this article was previously published on Pharmaphorum. Barely a day goes by without global warming or climate...

Medical Marijuana and Cannabinoids for Cancer Therapy

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially...

Biologics and Biosimilars in Oncology

With many patents about to expire in coming years, the field of biologics in oncology is about to change...

Sign up for NATALIE´s NEWSLETTER

WEBINARS & WHITEPAPERS

Gelesis Announces Partnership for Commercial Launch of Plenity® in China

BOSTON--(BUSINESS WIRE)--Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic...

CMOs of Pfizer and Sanofi give insight on their digital transformation

Comments and case studies from CMOs and Heads of Medical Affairs on how medical can use digital tools for...

Deliver patient-centered outcomes to be a trusted partner with AstraZeneca, Takeda and Novartis

Thanks to our ability to build a true partnership with our patients, we managed to gain trust and improve...

Time to Embrace Social Media Marketing | December 12 | NY 10:30 Am

  Unsurprisingly, patients and physicians are increasingly turning to social media to find information, make connections and communicate. But instead of...

Digitally transform medical affairs without compromising authenticity

Dear Colleagues: Within pharma companies, medical departments have steadily risen to prominence. As well as having a grip on key...

ON DEMAND WEBINAR: The evolving role of MSLs – insight from Amgen, Novartis and Pfizer

Dear Colleague 52% medical affairs experts believe that medical integrity is maintained in their organization – but is increasingly being...

Jorge Herrera

Jorge Herrera

Patient Experience is not Customer Experience and Pharma needs to get this.

The search volume of the term "Patient Experience" increased almost 550% in the past decade. Consultants, agencies, start ups and health care companies have been selling, exploring and adopting the concept, but what could be the ultimate goal? Improving an...

Jorge Herrera

Writer

JORGE HERRERA´S ARCHIVES

The digital game changers in pharma are not digital tools, but new aspirations

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the...

Suscribe to Jorge Herrera´s Newsletter

COVID-19

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of...

Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

CAMBRIDGE, Mass. & MADRID--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and...

Biorasi Kicks-Off Third COVID-19 Clinical Trial for 2020

MIAMI--(BUSINESS WIRE)--Biorasi, a leading global full-service contract research organization (CRO), has announced the start of the company’s third COVID-19...

Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial

MIAMI--(BUSINESS WIRE)--Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The...

CEPI Expands Partnership with Clover Biopharmaceuticals to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate

OSLO, Norway--(BUSINESS WIRE)--CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its partnership with Sichuan Clover...

Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS...